Last $27.21 USD
Change Today -0.81 / -2.91%
Volume 1.2M
EXAS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

exact sciences corp (EXAS) Snapshot

Open
$27.81
Previous Close
$28.03
Day High
$28.27
Day Low
$27.02
52 Week High
12/10/14 - $29.97
52 Week Low
05/8/14 - $10.69
Market Cap
2.4B
Average Volume 10 Days
1.2M
EPS TTM
$-1.03
Shares Outstanding
88.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EXACT SCIENCES CORP (EXAS)

exact sciences corp (EXAS) Related Bloomberg News

View More Bloomberg News

exact sciences corp (EXAS) Related Businessweek News

No Related Businessweek News Found

exact sciences corp (EXAS) Details

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company’s stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

102 Employees
Last Reported Date: 02/28/14
Founded in 1995

exact sciences corp (EXAS) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $738.5K
Principal Financial Officer and Senior Vice P...
Total Annual Compensation: $84.6K
Chief Operating Officer, Senior Vice Presiden...
Total Annual Compensation: $508.3K
Chief Science Officer and Senior Vice Preside...
Total Annual Compensation: $474.3K
Compensation as of Fiscal Year 2013.

exact sciences corp (EXAS) Key Developments

Exact Sciences Corp. Names Scott Coward as Senior Vice President and General Counsel

Exact Sciences Corp. reported that Scott Coward has been named Senior Vice President and General Counsel for the company. Most recently, he was managing partner of K&L Gates' Raleigh, N.C. office with a specialization in corporate, securities and M&A for life sciences companies.

Exact Sciences Corporation Provides Revenue Guidance for the Fourth Quarter of 2014

Exact Sciences Corporation provided revenue guidance for the fourth quarter of 2014. The company estimates revenue during the fourth quarter of 2014 from Cologuard was approximately $1.5 million.

Exact Sciences Corp. Names Scott Coward as Senior Vice President and General Counsel

Exact Sciences Corp. announced that Scott Coward has been named Senior Vice President and General Counsel for the company effective January 1, 2015. Coward brings with him decades of experience working with large corporations and emerging growth healthcare companies. Most recently, he was managing partner of K&L Gates’ Raleigh, N.C. office with a specialization in corporate, securities and M&A for life sciences companies. Coward counseled pharmaceutical and biotechnology companies spanning multiple disease states in areas including R&D, complex licensing, healthcare data and intellectual property. Prior to his tenure with K&L Gates, Coward held roles as General Counsel at Blue Rhino Corporation, Associate General Counsel at GE Medical Systems Information Technologies and Partner at Smith Anderson, one of the large law firms in North Carolina.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXAS:US $27.21 USD -0.81

EXAS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celldex Therapeutics Inc $21.42 USD -0.53
Curis Inc $1.84 USD -0.02
Delcath Systems Inc $1.24 USD -0.03
MELA Sciences Inc $1.38 USD -0.01
Navidea Biopharmaceuticals Inc $1.61 USD -0.10
View Industry Companies
 

Industry Analysis

EXAS

Industry Average

Valuation EXAS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,696.9x
Price/Book 10.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,652.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXACT SCIENCES CORP, please visit www.exactsciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.